Maple Grove, MN – August 19, 2022 — Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has divested two inactive ANDAs in an exclusive agreement with a New York-based pharmaceutical company. According to the terms of the agreement, the company will update the regulatory filing with the U.S. Food and Drug Administration prior to manufacturing the products. Upsher-Smith will retain the first right to commercialization under a profit share arrangement. Financial terms related to the deal have not been disclosed.
“Upsher-Smith’s focus remains on driving value from on-market products and optimizing its ANDA portfolio through strategic partnerships,” said Rich Fisher, President and COO, Upsher-Smith. “This agreement allows us to progress two dormant assets and contribute to the Company’s near-term profit.”
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to consistent product supply. For more information, visit www.upsher-smith.com.